ArticleJournal of addiction medicine2026
"The Sky Didn't Fall": Patient and Clinician Experiences With Increased Buprenorphine Prescription Lengths During Pandemic-related Telehealth Expansion.
Article in Journal of addiction medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesPandemic-related telehealth expansion changed how buprenorphine care was delivered. However, patient and clinician experiences with how these changes shaped decisions about prescription length remain underexplored, particularly in safety-net settings.
methodsFrom May 2021 to May 2022, we purposively sampled patients and clinicians from an office-based buprenorphine treatment clinic at an urban, safety-net hospital. Trained interviewers used semistructured interview guides to explore experiences with changes in care during the pandemic. We used a collaborative codebook development process and thematic analysis to identify key perspectives on buprenorphine prescription length changes.
resultsFrom interviews with 25 patients and 16 clinicians, 3 topics of relevance emerged: (1) changes to buprenorphine prescribing practices to support patients during the pandemic, (2) factors influencing clinical decision making and criteria for longer prescriptions, and (3) patient views and internalized expectations. Overall, both patients and providers reported increased duration of buprenorphine prescriptions and positive views of this change. Clinicians generally prioritized ensuring medication access over concerns about misuse and diversion. Influences on clinical decision making included medical conditions, transportation access, housing status, and patient communication. To receive longer prescriptions, some patients described deliberate efforts to build and maintain trust with clinicians.
conclusionsWe identified largely positive patient and clinician experiences with increased buprenorphine prescription lengths. As practices continue to update their clinic policies, these findings support continued flexibility and extended prescription lengths to support medication access. Findings also demonstrate heterogeneity in clinicians' decision-making and an opportunity for improved transparency and patient-provider communication regarding criteria for extended prescriptions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.